

# STUDY START-UP ACTIVITIES INITIATED

## Goals/ Definition

Start-up activities are initiated to enable timely. Phase 1 start.

Clinical study start-up plan initiated with consideration of feasibility and identification of risks.

CRITERIA	SAMPLE CONTENT REQUIREMENT	GUIDELINES FOR LEVEL OF DETAIL NEEDED AT EACH GATE
<ul style="list-style-type: none"> <li>Clinical trial designed</li> </ul>	<ul style="list-style-type: none"> <li>a) Protocol design and scope for Phase 1 (including study plans, medical monitoring plans, timelines and budgets) to support both NRA approval and WHO PQ</li> <li>b) An overview of the clinical development path (i.e., request for conditional approval) and rationales</li> <li>c) Updates to Investigator's Brochure for the next phase of development. (e.g., prior to First in Human include Core Safety Information from toxicology study)</li> </ul>	<ul style="list-style-type: none"> <li>Protocol synopsis</li> <li>Investigator Brochure</li> </ul>
<ul style="list-style-type: none"> <li>Clinical trial site feasibility completed</li> </ul>	<ul style="list-style-type: none"> <li>a) Plan for site assessment (may include audit) including considerations such as infrastructure, capability, supply chain feasibility, capacity, etc.</li> <li>b) Understanding of required approval process to conduct clinical studies at all potential study sites and identifying risks</li> </ul>	<ul style="list-style-type: none"> <li>Summary report</li> </ul>
<ul style="list-style-type: none"> <li>Clinical vendors/ CRO identified and site initiation activities conducted</li> </ul>	<ul style="list-style-type: none"> <li>a) Scope of work required (e.g., site selection, site initiation, data management, process &amp; method development, etc.) and agreed metrics to monitor trial progress</li> <li>b) Partner engagement strategy (e.g., outsourced activity, insourced activity, consultation, etc.)</li> <li>c) Examples of past vaccine trial experience in the disease area/geographic area</li> <li>d) Understanding of the stepwise clinical trial approval process, engaging with local regulatory authorities, ethics committee etc.</li> <li>e) Existing network of investigators and study sites</li> <li>f) Audit record of clinical study sites and track record of staff GCP training</li> <li>g) Completion of site initiation activities</li> </ul>	<ul style="list-style-type: none"> <li>Summary report</li> </ul>
<ul style="list-style-type: none"> <li>Clinical assay readiness</li> </ul>	<ul style="list-style-type: none"> <li>a) Relevant clinical assays need to be available prior to entering clinical studies</li> </ul>	<ul style="list-style-type: none"> <li>Summary of assay qualification</li> </ul>